Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation

– Gilead to License Special Around the globe Legal rights to the Investigational Candidate DF7001, a 5T4-Targeting NK Cell Engager for Sound Tumors –

– Gilead to Have Possibilities to License Various Extra NK Cell Engager Packages –

FOSTER Metropolis, Calif. & WALTHAM, Mass., May perhaps 02, 2022–(Company WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Dragonfly Therapeutics today introduced a collaboration made to progress a selection of Dragonfly’s novel organic killer (NK) cell engager-primarily based immunotherapies for oncology and irritation indications. NK cell engagers represent a novel system with the possible to handle a wide variety of cancers, together with potential for activity in checkpoint resistant and refractory tumors, as properly as other ailment places these kinds of as swelling. Under the settlement, Gilead will get an special, globally license from Dragonfly for the 5T4-concentrating on investigational immunotherapy application, DF7001. The settlement also grants Gilead possibilities, soon after the completion of specific preclinical activities, to license exceptional, around the world legal rights to develop and commercialize more NK cell engager systems applying the Dragonfly Tri-particular NK Engager (TriNKET™) platform. TriNKETs are activators of the innate and adaptive immune techniques, recruiting NK and cytotoxic T cells into the tumor microenvironment.

This push release features multimedia. Check out the total launch below: https://www.businesswire.com/information/house/20220429005730/en/

DF7001 is a TriNKET intended to activate and direct NK and cytotoxic T cell killing in opposition to cancer cells. The focus on of DF7001 is 5T4, a protein expressed on most cancers cells and stromal cells that guidance tumor advancement associated with lousy prognosis in numerous cancers, together with non-little cell lung cancer (NSCLC), pancreatic cancer, breast most cancers, and head and neck squamous cell carcinomas (HNSCC). DF7001 has the possible to result in the killing of 5T4+ expressing cells, including tumor cells, cancer-involved fibroblasts and most cancers stem cells. The plan is on track for submitting an Investigational New Drug (IND) application in the first half of 2023.

Tale continues

“We are excited to spouse with Dragonfly as we grow our pipeline with innovative NK mobile engager courses. Making use of our scientific framework to emphasis our endeavours, we are developing our portfolio with assets that have complementary MOAs and sturdy scientific rationale for mix possibilities,” reported Flavius Martin, MD, Government Vice President, Analysis at Gilead. “We glance ahead to working with the Dragonfly staff to take a look at novel NK engager remedies throughout diverse therapeutic spots to handle some of the best gaps in treatment for most cancers and inflammatory illnesses.”

“Gilead’s financial commitment in Dragonfly, and exclusively in DF7001, reinforces the benefit of our TriNKET system and the differentiated and sustainable tactic focused on people with most cancers and inflammatory illnesses,” explained Bill Haney, Co-Founder and Chief Executive Officer of Dragonfly. “Gilead has a nicely-founded track history in development and commercialization and is a perfectly-matched partner for our scientific expertise and platform. We seem forward to doing work with the Gilead staff to advance new therapy choices in which there is a superior unmet will need.”

Terms of the Agreement

Below the phrases of the agreement, Gilead will make a $300 million upfront payment to Dragonfly. In addition, Dragonfly is eligible to receive probable choose-in payments and performance-dependent progress, regulatory and professional milestone payments. Dragonfly will also be eligible to receive royalties of up to 20% on all over the world internet sales.

The transaction is issue to clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

DF7001 is an investigational product or service candidate it is not accredited by any regulatory agency for any use and has not been confirmed secure or efficacious.

About Dragonfly

Dragonfly Therapeutics, Inc. is a scientific-phase biopharmaceutical corporation fully commited to finding, establishing and commercializing therapies that use its novel TriNKET™ technologies to harness the body’s innate immune system to deliver breakthrough therapies to clients.

For more facts visit:
www.dragonflytx.com
https://www.linkedin.com/corporation/dragonfly-therapeutics-inc
https://twitter.com/dragonflytx

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical corporation that has pursued and attained breakthroughs in drugs for extra than three a long time, with the target of creating a much healthier earth for all people today. The firm is dedicated to advancing innovative medicines to reduce and take care of lifetime-threatening illnesses, together with HIV, viral hepatitis, most cancers, and irritation. Gilead operates in a lot more than 35 countries around the world, with headquarters in Foster City, California.

Gilead Forward-Hunting Statements

This press launch features forward-on the lookout statements within the that means of the Private Securities Litigation Reform Act of 1995 that are matter to threats, uncertainties and other aspects, which include the means of the get-togethers to entire the transaction in a timely manner or at all the risk that different closing situations for the transaction might not be content or waived, like the likelihood that a governmental entity could prohibit, delay or refuse to grant approval for the consummation of the transaction the threat that Gilead may perhaps not notice the opportunity rewards of this collaboration with Dragonfly or other investments in oncology troubles or unanticipated bills in connection with the collaboration and the opportunity effects on Gilead’s revenues and earnings the ability of the parties to initiate, development or comprehensive medical trials in just at this time predicted timelines or at all, and the risk of unfavorable results from ongoing or more trials, such as individuals involving DF7001 or any other NK cell engager system the potential of the get-togethers to file purposes for regulatory approval or receive regulatory approvals in a timely method or at all, which includes all those involving DF7001 or any other NK mobile engager software, and the hazard that any these approvals could be matter to considerable restrictions on use the likelihood that the parties may possibly make a strategic determination to terminate the collaborations, which includes the advancement of DF7001 or any other NK cell engager method, at any time and any assumptions fundamental any of the foregoing. These and other hazards, uncertainties and other things are described in depth in Gilead’s Yearly Report on Sort 10-K for the calendar year ended December 31, 2021, as filed with the U.S. Securities and Trade Fee. These hazards, uncertainties and other aspects could bring about precise benefits to differ materially from these referred to in the ahead-hunting statements. All statements other than statements of historical simple fact are statements that could be deemed forward-looking statements. The reader is cautioned that any this kind of forward-hunting statements are not assures of future general performance and include challenges and uncertainties, and is cautioned not to put undue reliance on these forward-on the lookout statements. All ahead-looking statements are centered on facts at the moment obtainable to Gilead, and Gilead assumes no obligation and disclaims any intent to update any these kinds of ahead-searching statements.

Gilead and the Gilead symbol are logos of Gilead Sciences, Inc., or its similar organizations.

For more data about Gilead, make sure you take a look at the company’s web site at www.gilead.com, observe Gilead on Twitter (@GileadSciences) or phone Gilead Community Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Watch resource model on businesswire.com: https://www.businesswire.com/information/residence/20220429005730/en/

Contacts

Gilead Contacts:
Jacquie Ross, Buyers
[email protected]

Jaisy Wagner Styles, Global Media
[email protected]

Dragonfly Call:
Anne Deconinck, Media
[email protected]